[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Vance Thompson Vision\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":150},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,64,87,108,121],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100054005","phase-4-efficacy-of-kera-sol-tears-on-signs-and-symptoms-of-surgical-temporary-ocular-discomfort-syndrome-stods-in-subjects-following-lasik-100054005",false,"NCT07155070","Efficacy of Kera Sol Tears on Signs and Symptoms of Surgical Temporary Ocular Discomfort Syndrome (STODS) in Subjects Following LASIK","Kera Sol Post-LASIK: A Benefit Study","Inclusion Criteria:\n\n* Be willing and able to sign the informed consent form (ICF)\n* Be at least 18 years of age at the screening visit\n* Be undergoing LASIK treatment in both eyes\n* Be literate and able to complete questionnaires independently\n* Be able and willing to use the study drug and participate in all study assessments and visits\n* Have provided verbal and written informed consent\n\nExclusion Criteria:\n\n* Use of topical prescription dry eye medications such as lifitegrast, cyclosporine, loltilaner, etc.\n* Have a break in the integrity of the corneal epithelium such as a persistent corneal epithelial defect, or corneal ulcer.\n* Have presence of corneal pathology that may interfere with LASIK outcomes\n* Active infectious, ocular or systemic disease\n* Have a history of ocular inflammation or macular edema\n* Have had clinically significant active infectious keratitis in the past 3 months 7. -Have history of prior refractive surgery\n* Have placement of temporary punctal plugs in the past 1 month or current presence of permanent punctal plugs at time of screening\n* Patients with usual relative and absolute contraindications for LASIK surgery (Patients with severe dry eye, recurrent corneal erosion, uncontrolled Glaucoma, collagen vascular disorders, keratoconus or signs of keratoconus, uncontrolled Diabetes, Herpes)\n* Autoimmune or immunodeficiency diseases\n* Pregnant or nursing women\n* Patients with history of previous ocular surgery, , except for previous cataract surgery.",true,"ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Collecting data using Kera Sol tear usage during the initial two-week post-operative period after Laser-Assisted In Situ Keratomileusis (LASIK) has on the signs and symptoms of surgical temporary ocular discomfort syndrome (STODS)",[27],"Dry Eye","RECRUITING","2026-07-09",{"date":31,"type":32},"2026-07-13","ACTUAL",{"date":34,"type":32},"2025-08-01",{"date":36,"type":21},"2027-02-01",{"name":38,"class":39},"Vance Thompson Vision","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100642261","phase-4-a-multicenter-open-label-study-to-evaluate-perioperative-treatment-of-dry-eye-with-miebo-in-subjects-undergoing-lasik-100642261","NCT07650708","A Multicenter, Open-Label Study to Evaluate Perioperative Treatment of Dry Eye With Miebo® in Subjects Undergoing LASIK","Sonoran","Inclusion Criteria:\n\n1. Be at least 18 years of age at the time of consent, able to provide written voluntary informed consent, willing to follow instructions and participate in all trial assessments and visits\n2. Be a candidate for routine, uncomplicated bilateral LASIK surgery (for spherical equivalent \\[≤-8.00D\\] myopia or myopic astigmatism correction, not combined with any other procedure; monovision myopic targets are allowed, however the myopic target eye will be the non-study \\[fellow\\] eye)\n3. No history of refractive surgery including implantable Collamer lens (ICL) or cataract surgery\n4. Total CFS score ≥1 and ≤6 using the National Eye Institute scale at Visit 1 (in at least one eye)\n5. Ocular Surface Disease Index (OSDI) ≥13 and ≤22 at Visit 1\n\nExclusion Criteria:\n\n1. Have any clinically significant ocular surface slit-lamp findings in the study eye that, in the opinion of the Investigator, could interfere with outcomes of a routine, uncomplicated LASIK surgery, including but not limited to:\n\n   1. History of eye trauma\u002Fsurgery within the last 6 months that resulted in corneal scarring\n   2. DED secondary to scarring, irradiation, alkali burns, cicatricial pemphigoid, or destruction of conjunctival goblet cells, Stevens-Johnson syndrome, active blepharitis, or lid margin inflammation\n   3. Abnormal cornea (e.g., keratoconus or corneal epithelial defect, pterygium, or history of herpetic keratitis)\n2. Use of any of the following ocular therapies in the study eye within 30 days prior to Visit 1: topical ocular steroid treatments, prescription dry eye therapy (including nasal spray), or topical intraocular pressure-lowering medications\n3. Use of any eye drops (prescription or over the counter) in the study eye within 24 hours prior to Visit 1\n4. Use of any oral medications known to cause ocular drying (e.g., antihistamines, antidepressants, etc.) on a non-stable regimen within 1 month prior to Visit 1 or is expected to be unstable during the trial\n5. Had a LipiFlow®, intense pulsed light (IPL) therapy, etc. in the study eye within 3 months prior to Visit 1\n6. Had received or removed a permanent punctum plug in the study eye within 1 month (3 months for dissolvable punctum plugs) prior to Visit 1\n7. Have worn soft contact lenses within either 3 days prior to the study or rigid gas-permeable contact lenses for 1 month prior to Visit 1 or any planned wear during the study\n8. Have undergone intraocular surgery or ocular laser surgery in the study eye within 3 months prior to Visit 1\n9. Have ocular allergies that are\u002Fexpected to be active during the trial period\n10. Have active ocular or systemic infection (bacterial, viral, or fungal), including fever\n11. Have any ocular findings or uncontrolled systemic disease that, in the opinion of the Investigator, will interfere with the trial\n12. Female subjects who are pregnant, nursing, or planning a pregnancy\n13. Female subjects of childbearing potential who are not using an acceptable means of birth control; acceptable methods of contraception include hormonal (oral, implantable, injectable, or transdermal) contraception; mechanical (spermicide in conjunction with a barrier such as a diaphragm or condom) contraception; intrauterine device; or surgical sterilization of partner. For non-sexually active female subjects, abstinence may be regarded as an adequate method of birth control; however, if the subject becomes sexually active during the trial, she must agree to use adequate birth control as defined above for the remainder of the trial.\n14. Have a known allergy and\u002For sensitivity or lack of desired efficacy in response to the investigational drug\n15. Are currently enrolled in an investigational drug or device study or had used an investigational drug or device within 30 days prior to Visit 1 -",{"count":49,"type":21},100,[24],"Compare eye dryness following laser-assisted in situ keratomileusis (LASIK) surgery to eye dryness prior to receiving perioperative Miebo in patients with dry eye disease (DED)",[53,54],"Dry Eye Syndrome (DES)","Dry Eye Disease (DED)","2026-06-19",{"date":57,"type":32},"2026-06-24",{"date":59,"type":32},"2026-05-05",{"date":61,"type":21},"2026-12-01",{"name":38,"class":39},4,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":22,"phases":72,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},"100623796","the-safety-and-efficacy-of-direct-slt-in-pseudoexfoliation-glaucoma-100623796","NCT07401290","The Safety and Efficacy of Direct SLT in Pseudoexfoliation Glaucoma","Inclusion Criteria:\n\n* Adult patients diagnosed with pseudoexfoliation glaucoma (PXFG), with optic neuropathy consistent with glaucomatous damage of any severity\n* Open iridocorneal angle by gonioscopy, defined as a Shafer Grade II or greater\n* Treatment naive, or washed out IOP ranging from ≥18-35 mmHg\n* Able to complete medication washout safely and all follow-up visits\n* Participants must have a best correct visual acuity of 20\u002F40 or better in the study eye(s), be able to undertake a reliable Humphrey visual field (HVF) (defined as fixation losses, false positives and false negatives less than 33%), and must have field loss no worse than -20 dB in treatment eye\n\nExclusion Criteria:\n\n* Any contraindication to SLT or unable to have DSLT\n* Angle closure glaucoma or any other types of glaucoma other than PXFG\n* Prior incisional glaucoma surgery or glaucoma-related procedures in the study eye\n* Any prior refractive surgery\n* H\u002Fo LPI within last 6 months\n* A history of any significant cataract required during study duration or cataract surgery in the last 6 months\n* Prior laser trabeculoplasty (ALT\u002FSLT)\n* History of ocular inflammation and infection\n* Patients who are pregnant or have any clinically relevant systemic disease that may prevent them from reliably completing follow-up visits\n* Vulnerable populations that cannot provide proper informed consent will not be enrolled, such as children, prisoners, handicapped, or mentally disabled persons, or economically or educationally disadvantaged persons",{"count":71,"type":21},40,[73],"NA","Prospective, multi-center, single arm, interventional study evaluating DSLT in patients with pseudoexfoliative glaucoma.",[76],"Pseudoexfoliation Glaucoma","NOT_YET_RECRUITING","2026-02-03",{"date":80,"type":32},"2026-02-10",{"date":82,"type":21},"2026-03",{"date":84,"type":21},"2028-03",{"name":38,"class":39},3,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":16,"sex":17,"minAge":95,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":22,"phases":97,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":40},"100604864","evaluating-crosslinked-hyaluronate-canalicular-gel-for-the-treatment-of-ded-in-patients-undergoing-cataract-surgery-100604864","NCT07155057","Evaluating Crosslinked Hyaluronate Canalicular Gel for the Treatment of DED in Patients Undergoing Cataract Surgery","A Prospective, Single-Arm Study Evaluating Crosslinked Hyaluronate Canalicular Gel for the Treatment of Dry Eye Disease in Patients Undergoing Refractive Cataract Surgery","LaReCa","Inclusion Criteria:\n\n* Be willing and able to understand and sign the informed consent form (ICF)\n* Men or non-pregnant women age 22 or older\n* Clear intraocular media other than cataract\n* Diagnosis of dry eye disease (OSDI score ≥ 13)\n* Non-invasive Tear break up time ≤ 10 seconds in at least one eye\n* Willing and able to comply with all study related visits and procedures\n* In the opinion of the investigator, patients who are appropriate for advanced technology lens implants\n\nExclusion Criteria:\n\n* History of punctal cautery\n* Lacrimal anatomy (e.g., nasolacrimal duct obstruction) that per investigator suggests that the patient would not be a good candidate for lacrimal occlusion or patients for whom lacrimal occlusion would increase risk","22 Years",{"count":20,"type":21},[73],"To review how patients report using a hyaluronate crosslinked canalicular gel placed before cataract surgery",[54],"2025-09-25",{"date":102,"type":32},"2025-09-29",{"date":104,"type":32},"2025-09-03",{"date":106,"type":21},"2026-12",{"name":38,"class":39},{"id":109,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":25,"conditions":113,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":118,"leadSponsor":120,"locationsCount":40},"100604865","Inclusion Criteria:\n\n* Be willing and able to sign the informed consent form (ICF)\n* Be at least 18 years of age at the screening visit\n* Be undergoing LASIK treatment in both eyes\n* Be literate and able to complete questionnaires independently\n* Be able and willing to use the study drug and participate in all study assessments and visits\n* Have provided verbal and written informed consent\n\nExclusion Criteria:\n\n* Use of topical prescription dry eye medications such as lifitegrast, cyclosporine, loltilaner, etc.\n* Have a break in the integrity of the corneal epithelium such as a persistent corneal epithelial defect, or corneal ulcer.\n* Have presence of corneal pathology that may interfere with LASIK outcomes\n* Active infectious, ocular or systemic disease\n* Have a history of ocular inflammation or macular edema\n* Have had clinically significant active infectious keratitis in the past 3 months 7. -Have history of prior refractive surgery\n* Have placement of temporary punctal plugs in the past 1 month or current presence of permanent punctal plugs at time of screening\n* Patients with usual relative and absolute contraindications for LASIK surgery (Patients with severe dry eye, recurrent corneal erosion, uncontrolled Glaucoma, collagen vascular disorders, keratoconus or signs of keratoconus, uncontrolled Diabetes, Herpes)\n* Autoimmune or immunodeficiency diseases\n* Pregnant or nursing women\n* Patients with history of previous ocular surgery",{"count":20,"type":21},[24],[27],"2025-09-04",{"date":116,"type":32},"2025-09-11",{"date":34,"type":32},{"date":119,"type":21},"2026-02-01",{"name":38,"class":39},{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":129,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":149},"100569916","measuring-outcomes-of-lasik-and-evo-icl-in-matched-populations-100569916","NCT06700460","Measuring Outcomes of LASIK and EVO-ICL in Matched Populations","A Randomized Evaluation of Clinical Outcomes Following Bilateral Implantation of EVO+ ICL Lenses or Bilateral Wavefront-Optimized LASIK (EVOlve)","EVOlve","Inclusion Criteria:\n\n* Preoperatively the Investigator will evaluate each study subject and refer to the directions for use for EVO+ ICL and Wavefront-Optimized LASIK to confirm the subject's suitability to proceed with bilateral EVO+ ICL Implantation or bilateral Wavefront-optimized LASIK in accordance with the Investigator's standard of care for each procedure. To ensure similar characteristics across study subjects, the Investigator will also adhere to the following criteria for each group:\n\n  1. Subjects ages 21 to 45 years old.\n  2. Stable refractive error for at least one year (≤ 0.50 D change in refraction) or stability as determined by the Investigator.\n  3. Myopia or myopia with astigmatism with spherical equivalent ranging from -3.00 D to ≤ -8.00 D (in the spectacle plane) and cylinder in the range of 0.00 D to 4.00 D (in the spectacle plane).\n  4. Corrected distance visual acuity (CDVA) of 20\u002F20 or better in each eye.\n  5. Difference between cycloplegic refraction spherical equivalent (CRSE) and manifest refraction spherical equivalent (MRSE) of ≤0.75 D.\n  6. Subjects must be able and willing to return for scheduled follow-up examinations after surgery.\n  7. Subjects must be able to read, understand and provide written informed consent on the Institutional Review Board (IRB) approved Informed Consent Form (ICF) and provide authorization as appropriate for local privacy regulations.\n\nExclusion Criteria:\n\n* 1\\. Pregnant or nursing women, or those who plan to become pregnant over the course of this clinical study or has another condition with associated fluctuation of hormones that could lead to refractive changes.\n\n  2\\. Dry eye syndrome that is unable to be controlled with ocular lubricant(s) or medication(s) and which may confound study outcomes in the opinion of the Investigator.\n\n  3\\. Serious acute, chronic, or systemic, non-ophthalmic disease or illness that would increase the operative risk, confound the outcome(s) of the study or which may preclude study completion (e.g., immunocompromised, connective tissue disease, clinically significant atopic disease, uncontrolled diabetes, etc.), in the opinion of the Investigator.\n\n  4\\. Ocular condition (other than high myopia) that may predispose the subject to future complications, in the opinion of the Investigator. For example:\n  * Pigment dispersion,\n  * History or clinical signs of iritis\u002Fuveitis,\n  * History of previous ocular surgery,\n  * Monocular subjects,\n  * History or evidence of active or inactive corneal disease (e.g., herpes simplex keratitis, herpes zoster keratitis, recurrent corneal erosion syndrome, corneal dystrophy, etc.),\n  * Evidence of retinal vascular disease,\n  * Keratoconus or keratoconus suspect,\n  * Glaucoma or glaucoma suspect by exam findings,\n  * Ocular surface disease other than controlled dry eye syndrome. 5. Subjects who do not qualify for both study arms:\n  * Bilateral Wavefront Optimized LASIK\n  * Bilateral EVO+ ICL implantation\n\n    6\\. Subjects who, in the judgment of the Investigator, present any emotional, physiologic, or anatomical condition which may preclude participation in this study or provide an inappropriate landscape for the intended study treatment.\n\n    7\\. Participation in another clinical trial involving ocular procedures within the last 6-months.\n\n    8\\. Other conditions or assessment that causes the subject to not be an acceptable candidate for treatment or study participation as clinically assessed and documented by the Investigator.","21 Years","45 Years",{"count":132,"type":21},56,[73],"Evaluating outcomes after bilateral implantation of ICLs or bilateral LASIK as treatment options for the correction or reduction of myopia with or without astigmatism.",[136],"Myopia",[138,139,136,140],"LASIK","EVO ICL","Clinical Outcomes","2025-01-07",{"date":143,"type":32},"2025-01-09",{"date":145,"type":32},"2024-11-27",{"date":147,"type":21},"2025-04-01",{"name":38,"class":39},5,""]